文献速递艾滋病与性传播感染

既往NRTI和NNRTI耐药对换用TDF/FTC/RPV单片制剂后病毒学抑制维持的影响

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

72周时病毒学反弹(VR)概率为11.3%;

要点

  • 换用TDF/FTC/RPV简化治疗后72周VR概率为11.3%,总体维持病毒学抑制率较高。
  • 对NRTI和NNRTI均存在既往耐药者VR风险显著升高(39.2% vs 11.5% vs 9.4%)。

核心结论

  • TDF/FTC/RPV作为简化治疗策略显示出很高的病毒学抑制维持率。
  • 简化治疗前需准确筛选患者以降低病毒学反弹风险。

研究设计与样本

  • 根据既往所有血浆基因型耐药检测结果评估既往耐药(pRes)。
  • 评估病毒学反弹(VR)的概率及预测因素。

主要发现

  • 5.8%的患者对NRTI和NNRTI均存在耐药,12.6%仅对其中一类药物耐药。
  • 72周时病毒学反弹概率为11.3%。
  • 对NRTI+NNRTI既往耐药者VR概率为39.2%,仅对NRTI或NNRTI耐药者为11.5%,无逆转录酶抑制剂既往耐药者为9.4%(P < 0.0001)。
  • 病毒对TDF/FTC和RPV均完全/部分耐药者VR概率为36.4%,对其中之一耐药者为17.8%,对TDF/FTC/RPV完全敏感者为9.7%(P < 0.001)。

关键数值与推荐

  • 对NRTI和NNRTI均存在既往耐药者72周VR概率为39.2%(P < 0.0001)。
  • 病毒对TDF/FTC和RPV均完全/部分耐药者VR概率为36.4%(P < 0.001)。

临床怎么用

  • 对已实现病毒学抑制的HIV-1感染者,换用TDF/FTC/RPV单片制剂前应评估既往耐药情况。
  • 无逆转录酶抑制剂既往耐药且治疗前病毒载量较低者,换用TDF/FTC/RPV后病毒学抑制维持率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes). METHODS: pRes was evaluated according to resistance on all previous plasma genotypic resistance tests. Probability and predictors of virological rebound (VR) were evaluated. RESULTS: Three hundred and nine patients were analysed; 5.8% of them showed resistance to both NRTIs and NNRTIs, while 12.6% showed resistance to only one of these drug classes. By 72 weeks, the probability of VR was 11.3%. A higher probability of VR was found in the following groups: (i) patients with NRTI + NNRTI pRes compared with those harbouring NRTI or NNRTI pRes and with those without reverse transcriptase inhibitor pRes (39.2% versus 11.5% versus 9.4%, P < 0.0001); (ii) patients with a virus with full/intermediate resistance to both tenofovir/emtricitabine and rilpivirine compared with those having a virus with full/intermediate resistance to tenofovir/emtricitabine or rilpivirine and those having a virus fully susceptible to TDF/FTC/RPV (36.4% versus 17.8% versus 9.7%, P < 0.001); and (iii) patients with pre-therapy viraemia >500 000 copies/mL compared with those with lower viraemia levels (>500 000: 16.0%; 100 000-500 000: 9.3%; <100 000 copies/mL: 4.8%, P = 0.009). pRes and pre-therapy viraemia >500 000 copies/mL were independent predictors of VR by multivariable Cox regression. CONCLUSIONS: TDF/FTC/RPV as a treatment simplification strategy shows a very high rate of VS maintenance. The presence of pRes to both NRTIs and NNRTIs and a pre-therapy viraemia >500 000 copies/mL are associated with an increased risk of VR, highlighting the need for an accurate selection of patients before simplification.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Armenia D, Di Carlo D, Calcagno A, et al. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. J Antimicrob Chemother. 2017. PMID: 27999048. doi:10.1093/jac/dkw512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。